Last reviewed · How we verify
NCT02430701: IRE
Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms
NA trial testing Irreversible electroporation (IRE) in Esophageal Neoplasms in 30 participants. Completed in 1 April 2021.
1 December 2020
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 January 2015 |
| Primary completion | 1 December 2020 |
| Estimated completion | 1 April 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Irreversible electroporation (IRE)
- NanoKnife
Conditions studied
- Esophageal Neoplasms — all drugs for Esophageal Neoplasms →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Eligibility, any sex, with Esophageal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Esophageal Neoplasms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02430701
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Irreversible electroporation (IRE)
Trials testing the same drug.
- NCT05435053 — Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer · Phase 2 · terminated
- NCT02430597 — Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms · NA · completed
- NCT02430675 — Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms · NA · completed
- NCT02335112 — Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms · NA · completed
- NCT02430662 — Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms · NA · completed
Other recruiting trials for Esophageal Neoplasms
Currently open trials in the same condition.
- NCT07482566 — Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer · NA · recruiting
- NCT07272382 — Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer · NA · recruiting
- NCT06469944 — Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First · Phase 1, PHASE2 · recruiting
- NCT07035587 — Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity · recruiting
- NCT06445972 — Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) · Phase 1, PHASE2 · recruiting
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02430701 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 5 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02430701.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing